Beroni Group Ltd: Business Overview, Financials & Competitive Analysis
Beroni Group Ltd scores 4/10 on the AskCyborg Cyborg Score (Mixed). Diversified biopharma portfolio with infrastructure across multiple therapeutic areas, but severely constrained by micro-cap status and OTC trading liquidity. Beroni operates in high-growth biopharmaceutical and diagnostic markets but trades as a penny stock (OTC at $0.0064 as of March 2026) with minimal market capitalization (~$180K). The company has diversified.
What is Beroni Group Ltd's industry? Beroni Group Ltd (beronigroup.com) operates in In-Vitro Diagnostics. AskCyborg classifies Beroni Group Ltd under In-Vitro Diagnostics in its company registry.
Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its dive...
Cyborg Score thesis
Diversified biopharma portfolio with infrastructure across multiple therapeutic areas, but severely constrained by micro-cap...
Read the full analyst-debate transcript →Get the Latest Beroni Group Ltd Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBeroni Group Ltd Overview
Pro stress-test →Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies.
Strategic Profile
Pro stress-test →The company operates through four segments: Cell Therapies; Developing New Anti-Cancer Drugs; E-commerce Platform for Pharmaceutical and Healthcare Products; and Detection & Diagnosis of Infectious Diseases. Beroni has operations in Australia, United States, China and Japan.
Competitive Landscape
Pro stress-test →Beroni competes in fragmented markets across diagnostics (vs. major IVD manufacturers like Abbott, Roche), cell therapy (vs. established biotech firms), and pharmaceutical e-commerce (vs. online pharmacy platforms). The company's diversification across uncorrelated markets reduces direct competition but limits scale advantages in any single segment.
Industry Context
Beroni Group Ltd operates in In-Vitro Diagnostics.
Key facts
Founded: N/A · Headquarters: Sydney, Australia · Employees: N/A · Revenue: N/A · Market cap: $180K (as of March 2026)